Ji Sun Park

Ji Sun Park is an accomplished scientist with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as a Scientist and previously as a Principal Associate Scientist at Alnylam Pharmaceuticals, Ji Sun Park has contributed significantly to rare disease research, notably preparing data packages for IND approval and utilizing CRISPR Cas9 for gene editing. Professional history includes roles such as Principal Research Associate at Moderna and Codiak BioSciences, where Ji Sun Park focused on exosome engineering and therapeutic target validation. A strong background in molecular biology is complemented by research positions at prestigious institutions like the Harvard Stem Cell Institute and the Massachusetts General Hospital Research Institute, with multiple co-authored publications in high-impact journals. Ji Sun Park holds both a Master’s and Bachelor’s Degree in Oncology and Cancer Biology and Biology from Incheon National University.